The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Salvage Therapy

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Salvage Therapy


Psychiatry related information on Salvage Therapy


High impact information on Salvage Therapy

  • As part of the Third International Workshop on WM, held October 7 to 10, 2004 in Paris, France, a consensus panel charged with providing treatment recommendations for WM updated its recommendations on both frontline and salvage therapies [7].
  • Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure [8].
  • In patients without poor prognostic features, single-agent imatinib may be appropriate before transplant salvage therapy [9].
  • OBJECTIVE: To assess the genotypic determinants of the virological response to tenofovir disoproxil fumarate (TDF) in a multicentre cohort of antiretroviral (ARV)-experienced patients receiving TDF as a part of a salvage therapy [10].
  • Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling [11].

Chemical compound and disease context of Salvage Therapy


Biological context of Salvage Therapy


Anatomical context of Salvage Therapy


Associations of Salvage Therapy with chemical compounds


Gene context of Salvage Therapy


Analytical, diagnostic and therapeutic context of Salvage Therapy


  1. Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. Döhner, H., Ho, A.D., Thaler, J., Stryckmans, P., Sonneveld, P., de Witte, T., Lechner, K., Lauria, F., Bödewadt-Radzun, S., Suciu, S. J. Natl. Cancer Inst. (1993) [Pubmed]
  2. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Jagannath, S., Dicke, K.A., Armitage, J.O., Cabanillas, F.F., Horwitz, L.J., Vellekoop, L., Zander, A.R., Spitzer, G. Ann. Intern. Med. (1986) [Pubmed]
  3. Thalidomide as salvage therapy for chronic graft-versus-host disease. Parker, P.M., Chao, N., Nademanee, A., O'Donnell, M.R., Schmidt, G.M., Snyder, D.S., Stein, A.S., Smith, E.P., Molina, A., Stepan, D.E., Kashyap, A., Planas, I., Spielberger, R., Somlo, G., Margolin, K., Zwingenberger, K., Wilsman, K., Negrin, R.S., Long, G.D., Niland, J.C., Blume, K.G., Forman, S.J. Blood (1995) [Pubmed]
  4. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Emilia, G., Morselli, M., Luppi, M., Longo, G., Marasca, R., Gandini, G., Ferrara, L., D'Apollo, N., Potenza, L., Bertesi, M., Torelli, G. Blood (2002) [Pubmed]
  5. Adverse effects of intraperitoneal fluorouracil in patients with optimal residual ovarian cancer after second-look laparotomy: a Gynecologic Oncology Group Study. Walton, L.A., Blessing, J.A., Homesley, H.D. J. Clin. Oncol. (1989) [Pubmed]
  6. High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction. Seftel, A. J. Urol. (2003) [Pubmed]
  7. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Treon, S.P., Gertz, M.A., Dimopoulos, M., Anagnostopoulos, A., Blade, J., Branagan, A.R., Garcia-Sanz, R., Johnson, S., Kimby, E., Leblond, V., Fermand, J.P., Maloney, D.G., Merlini, G., Morel, P., Morra, E., Nichols, G., Ocio, E.M., Owen, R., Stone, M.J. Blood (2006) [Pubmed]
  8. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Raguin, G., Chêne, G., Morand-Joubert, L., Taburet, A.M., Droz, C., Le Tiec, C., Clavel, F., Girard, P.M. Antivir. Ther. (Lond.) (2004) [Pubmed]
  9. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. Wassmann, B., Pfeifer, H., Scheuring, U.J., Binckebanck, A., Gökbuget, N., Atta, J., Brück, P., Rieder, H., Schoch, C., Leimer, L., Schwerdtfeger, R., Ehninger, G., Lipp, T., Perz, J., Stelljes, M., Gschaidmeier, H., Hoelzer, D., Ottmann, O.G. Blood (2004) [Pubmed]
  10. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Masquelier, B., Tamalet, C., Montès, B., Descamps, D., Peytavin, G., Bocket, L., Wirden, M., Izopet, J., Schneider, V., Ferré, V., Ruffault, A., Palmer, P., Trylesinski, A., Miller, M., Brun-Vézinet, F., Costagliola, D. Antivir. Ther. (Lond.) (2004) [Pubmed]
  11. Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling. Maggiolo, F., Callegaro, A., Arici, C., Quinzan, G., Gregis, G., Ripamonti, D., Tebaldi, A., Goglio, A., Suter, F. Antivir. Ther. (Lond.) (2003) [Pubmed]
  12. Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. Doroshow, J.H., Leong, L., Margolin, K., Flanagan, B., Goldberg, D., Bertrand, M., Akman, S., Carr, B., Odujinrin, O., Newman, E. J. Clin. Oncol. (1989) [Pubmed]
  13. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. Amadori, S., Arcese, W., Isacchi, G., Meloni, G., Petti, M.C., Monarca, B., Testi, A.M., Mandelli, F. J. Clin. Oncol. (1991) [Pubmed]
  14. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. Ramanathan, R.K., Clark, J.W., Kemeny, N.E., Lenz, H.J., Gococo, K.O., Haller, D.G., Mitchell, E.P., Kardinal, C.G. J. Clin. Oncol. (2003) [Pubmed]
  15. Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. Valer, L., De Mendoza, C., De Requena, D.G., Labarga, P., García-Henarejos, A., Barreiro, P., Guerrero, F., Vergara, A., Soriano, V. AIDS (2002) [Pubmed]
  16. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. Lorenzi, P., Opravil, M., Hirschel, B., Chave, J.P., Furrer, H.J., Sax, H., Perneger, T.V., Perrin, L., Kaiser, L., Yerly, S. AIDS (1999) [Pubmed]
  17. Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. Boffito, M., Arnaudo, I., Raiteri, R., Bonora, S., Sinicco, A., Di Garbo, A., Reynolds, H.E., Hoggard, P.G., Back, D.J., Di Perri, G. AIDS (2002) [Pubmed]
  18. Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy. Khanlou, H., Graham, E., Brill, M., Farthing, C. AIDS (2002) [Pubmed]
  19. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Kern, W., Schoch, C., Haferlach, T., Braess, J., Unterhalt, M., Wörmann, B., Büchner, T., Hiddemann, W. Leukemia (2000) [Pubmed]
  20. Resistance testing in children changing human immunodeficiency virus type 1 protease inhibitor. Servais, J., Hainaut, M., Schmitz, V., Maes, P., Fransen, K., Vaira, D., Brichard, B., Arendt, V., Schneider, F., Hemmer, R., Schmit, J.C. Pediatr. Infect. Dis. J. (2002) [Pubmed]
  21. Therapeutic Intervention Scoring System used in the care of patients in pentobarbital-induced coma to determine nurse-patient ratios. Myles, G.L., Malkoff, M.D., Perry, A.G., Bucholz, R.D., Gomez, C.R. Am. J. Crit. Care (1996) [Pubmed]
  22. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. Motzer, R.J., Mazumdar, M., Sheinfeld, J., Bajorin, D.F., Macapinlac, H.A., Bains, M., Reich, L., Flombaum, C., Mariani, T., Tong, W.P., Bosl, G.J. J. Clin. Oncol. (2000) [Pubmed]
  23. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Bokemeyer, C., Beyer, J., Metzner, B., Ruther, U., Harstrick, A., Weissbach, L., Kohrmann, U., Verbeek, W., Schmoll, H.J. Ann. Oncol. (1996) [Pubmed]
  24. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Marotta, G., Bigazzi, C., Lenoci, M., Tozzi, M., Bocchia, M., Lauria, F. Haematologica (2000) [Pubmed]
  25. A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials. Thall, P.F., Estey, E.H., Sung, H.G. Investigational new drugs. (1999) [Pubmed]
  26. First experiences and perspectives for the use of cytokines in the treatment of non-Hodgkin's lymphoma. Engelhard, M. Anticancer Drugs (1993) [Pubmed]
  27. Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy. Walter, H., Schmidt, B., Rascu, A., Helm, M., Moschik, B., Paatz, C., Kurowski, M., Korn, K., Uberla, K., Harrer, T. Antivir. Ther. (Lond.) (2000) [Pubmed]
  28. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. Leblond, V., Lévy, V., Maloisel, F., Cazin, B., Fermand, J.P., Harousseau, J.L., Remenieras, L., Porcher, R., Gardembas, M., Marit, G., Deconinck, E., Desablens, B., Guilhot, F., Philippe, G., Stamatoullas, A., Guibon, O. Blood (2001) [Pubmed]
  29. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Kreitman, R.J., Wilson, W.H., Robbins, D., Margulies, I., Stetler-Stevenson, M., Waldmann, T.A., Pastan, I. Blood (1999) [Pubmed]
  30. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Reece, D.E., Connors, J.M., Spinelli, J.J., Barnett, M.J., Fairey, R.N., Klingemann, H.G., Nantel, S.H., O'Reilly, S., Shepherd, J.D., Sutherland, H.J. Blood (1994) [Pubmed]
  31. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Kantarjian, H.M., Cortes, J., O'Brien, S., Giles, F.J., Albitar, M., Rios, M.B., Shan, J., Faderl, S., Garcia-Manero, G., Thomas, D.A., Resta, D., Talpaz, M. Blood (2002) [Pubmed]
  32. Endothelin-a receptor antagonist treatment improves the periosteal microcirculation after hindlimb ischemia and reperfusion in the rat. Wolfárd, A., Császár, J., Gera, L., Petri, A., Simonka, J.A., Balogh, A., Boros, M. Microcirculation (New York, N.Y. : 1994) (2002) [Pubmed]
  33. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy. Huan, S.Y., Yang, C.H., Chen, Y.C. Leuk. Lymphoma (2000) [Pubmed]
  34. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. Ritter, M.A., Messing, E.M., Shanahan, T.G., Potts, S., Chappell, R.J., Kinsella, T.J. J. Clin. Oncol. (1992) [Pubmed]
  35. Treatment of relapse after autologous blood stem cell transplantation for severe rheumatoid arthritis. Pavletic, S.Z., Klassen, L.W., Pope, R., O'Dell, J.R., Traynor, A.E., Haire, C.E., Graziano, F., Oyama, Y., Barr, W., Burt, R.K. The Journal of rheumatology. Supplement. (2001) [Pubmed]
  36. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Gribben, J.G., Ryan, D.P., Boyajian, R., Urban, R.G., Hedley, M.L., Beach, K., Nealon, P., Matulonis, U., Campos, S., Gilligan, T.D., Richardson, P.G., Marshall, B., Neuberg, D., Nadler, L.M. Clin. Cancer Res. (2005) [Pubmed]
  37. Accumulation of lopinavir resistance-associated mutations over 3 years follow-up of patients on highly active antiretroviral therapy: implication in salvage therapy. Tsuchiya, K., Matsuoka, S., Hachiya, A., Yasuoka, A., Tachikawa, N., Kikuchi, Y., Genka, I., Teruya, K., Kimura, S., Oka, S. AIDS (2001) [Pubmed]
  38. Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG protocol 093). AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. Jacobson, M.A., Wulfsohn, M., Feinberg, J.E., Davis, R., Power, M., Owens, S., Causey, D., Heath-Chiozzi, M.E., Murphy, R.L., Cheung, T.W. AIDS (1994) [Pubmed]
  39. Use of liquid ventilation with perflubron during extracorporeal membrane oxygenation: chest radiographic appearances. Gross, G.W., Greenspan, J.S., Fox, W.W., Rubenstein, S.D., Wolfson, M.R., Shaffer, T.H. Radiology. (1995) [Pubmed]
  40. Thalidomide in the management of multiple myeloma. Barlogie, B., Tricot, G., Anaissie, E. Semin. Oncol. (2001) [Pubmed]
  41. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study. Resino, S., Bellón, J.M., Ramos, J.T., Gonzalez-Rivera, M., de José, M.I., González, M.I., Gurbindo, D., Mellado, M.J., Cabrero, E., Muñoz-Fernández, M.A. J. Antimicrob. Chemother. (2004) [Pubmed]
WikiGenes - Universities